IBRX
Immunitybio Inc
8.60$
-7.1%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +69.5% | -71.2% | +2,517.5% | +483.2% | +23.7% | +118.7% | +60.0% | +21.3% | +19.4% | +15.5% | +15.9% | – | |
| – | -0.5% | -0.2% | -3.3% | -96.6% | +2,622.4% | -98.6% | +134.5% | +2,935.3% | +2.9% | -94.4% | +25.2% | – | |
| – | +69.5% | -71.2% | +2,517.5% | +483.2% | +23.7% | +117.9% | +59.7% | +6.3% | +21.9% | +29.2% | +15.9% | – | |
| – | +6.5% | +3.5% | -4.2% | -1.3% | -30.2% | +36.9% | +14.5% | -8.2% | +19.9% | +6.5% | -10.9% | – | |
| – | +4.1% | +26.5% | +17.6% | -27.1% | +16.2% | -21.8% | +29.7% | -14.3% | +6.7% | +18.2% | +13.2% | – | |
| – | +6.6% | +11.4% | +5.4% | -14.0% | -10.9% | +5.1% | +20.6% | -14.4% | +18.1% | +15.2% | -1.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -8.3% | +16.7% | +4.1% | +3.1% | -63.0% | +93.7% | +0.1% | -4.5% | -1.4% | +4.7% | -99.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -1,476.5% | – | -113.0% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.